Challenges in Molecular Monitoring for CML Treatment Response
This video examines the challenge in optimizing and standardizing molecular monitoring for patients with chronic myeloid leukemia.
The success of tyrosine kinase inhibitors (TKIs) for the treatment of chronic myeloid leukemia (CML) has brought about the need to improve molecular monitoring in this patient population.
In this video, Susan Branford, MD, of the Centre for Cancer Biology and University of Adelaide, Australia, discusses some of the challenges in optimizing and standardizing molecular monitoring to an international reporting scale.
Branford highlights the potential need to move away from molecular milestones at 3, 6, and 12 months of TKI therapy and the variability among molecular assays that present a challenge in assessing response.
![We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fd5a069c33bbfe917bc7c0b1bb13d76c0a815cc44-234x234.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
